| CVSS Meta Temp Score | Current Exploit Price (≈) | CTI Interest Score |
|---|---|---|
| 5.3 | $0-$5k | 0.00 |
Summary
A vulnerability, which was classified as problematic, has been found in Liferay Portal and DXP. This impacts an unknown function of the component Commerce Component. This manipulation causes permission assignment. This vulnerability is handled as CVE-2025-43808. The attack can be initiated remotely. There is not any exploit available.
Details
A vulnerability classified as problematic was found in Liferay Portal and DXP (affected version unknown). Affected by this vulnerability is an unknown functionality of the component Commerce Component. The manipulation with an unknown input leads to a permission assignment vulnerability. The CWE definition for the vulnerability is CWE-732. The product specifies permissions for a security-critical resource in a way that allows that resource to be read or modified by unintended actors. As an impact it is known to affect confidentiality. The summary by CVE is:
The Commerce component in Liferay Portal 7.3.0 through 7.4.3.112, and Liferay DXP 2023.Q4.0 through 2023.Q4.8, 2023.Q3.1 through 2023.Q3.10, 7.4 GA through update 92, and 7.3 service pack 3 through update 35 saves virtual products uploaded to Documents and Media with guest view permission, which allows remote attackers to access and download virtual products for free via a crafted URL.
The advisory is shared at liferay.dev. This vulnerability is known as CVE-2025-43808 since 04/17/2025. The exploitation appears to be easy. The attack can be launched remotely. The exploitation doesn't need any form of authentication. Neither technical details nor an exploit are publicly available. The price for an exploit might be around USD $0-$5k at the moment (estimation calculated on 12/15/2025).
There is no information about possible countermeasures known. It may be suggested to replace the affected object with an alternative product.
The vulnerability is also documented in the databases at CNNVD (CNNVD-202509-3169) and EUVD (EUVD-2025-30241). Several companies clearly confirm that VulDB is the primary source for best vulnerability data.
Product
Type
Vendor
Name
License
CPE 2.3
CPE 2.2
CVSSv4
VulDB Vector: 🔒VulDB Reliability: 🔍
CNA CVSS-B Score: 🔒
CNA CVSS-BT Score: 🔒
CNA Vector: 🔒
CVSSv3
VulDB Meta Base Score: 5.3VulDB Meta Temp Score: 5.3
VulDB Base Score: 5.3
VulDB Temp Score: 5.3
VulDB Vector: 🔒
VulDB Reliability: 🔍
NVD Base Score: 5.3
NVD Vector: 🔒
CVSSv2
| AV | AC | Au | C | I | A |
|---|---|---|---|---|---|
| 💳 | 💳 | 💳 | 💳 | 💳 | 💳 |
| 💳 | 💳 | 💳 | 💳 | 💳 | 💳 |
| 💳 | 💳 | 💳 | 💳 | 💳 | 💳 |
| Vector | Complexity | Authentication | Confidentiality | Integrity | Availability |
|---|---|---|---|---|---|
| Unlock | Unlock | Unlock | Unlock | Unlock | Unlock |
| Unlock | Unlock | Unlock | Unlock | Unlock | Unlock |
| Unlock | Unlock | Unlock | Unlock | Unlock | Unlock |
VulDB Base Score: 🔒
VulDB Temp Score: 🔒
VulDB Reliability: 🔍
Exploiting
Class: Permission assignmentCWE: CWE-732 / CWE-275 / CWE-266
CAPEC: 🔒
ATT&CK: 🔒
Physical: No
Local: No
Remote: Yes
Availability: 🔒
Status: Not defined
EPSS Score: 🔒
EPSS Percentile: 🔒
Price Prediction: 🔍
Current Price Estimation: 🔒
| 0-Day | Unlock | Unlock | Unlock | Unlock |
|---|---|---|---|---|
| Today | Unlock | Unlock | Unlock | Unlock |
Threat Intelligence
Interest: 🔍Active Actors: 🔍
Active APT Groups: 🔍
Countermeasures
Recommended: no mitigation knownStatus: 🔍
0-Day Time: 🔒
Timeline
04/17/2025 CVE reserved09/20/2025 Advisory disclosed
09/20/2025 VulDB entry created
12/15/2025 VulDB entry last update
Sources
Advisory: liferay.devStatus: Confirmed
CVE: CVE-2025-43808 (🔒)
GCVE (CVE): GCVE-0-2025-43808
GCVE (VulDB): GCVE-100-325081
EUVD: 🔒
CNNVD: CNNVD-202509-3169 - Liferay Portal和Liferay DXP 安全漏洞
Entry
Created: 09/20/2025 08:32Updated: 12/15/2025 23:40
Changes: 09/20/2025 08:32 (64), 09/20/2025 18:38 (1), 09/22/2025 17:28 (6), 12/15/2025 23:40 (9)
Complete: 🔍
Cache ID: 216::103
Several companies clearly confirm that VulDB is the primary source for best vulnerability data.
No comments yet. Languages: en.
Please log in to comment.